From: The role of amputation as an outcome measure in cellular therapy for critical limb ischemia: implications for clinical trial design
N
Amp N
Amp %
Jivegard 1995
26
10
38.5%
Lepantalo 1996
136
53
39.0%
Klomp 1999
60
20
33.3%
Amann 2003
39
15
Brass 2006
190
16
8.4%
Nikol 2008
56
28.6%
Hiatt 2010
259
44
17.0%
Powell 2011
24
6
25.0%
Benoit 2011
14
5
35.7%
804
185
23.0%